Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) CEO David Elsley joined Steve Darling from Proactive to share news the company has closed their public offering of 16,350,000 units of the Company for a price of US$3.07 per share for gross proceeds of just over 50 million U.S. .
Elsley telling Proactive the demand they saw during the capital raise and where this puts the company in their sector. He also talks about how they plan on using that money as they continue down the road of clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease.